65,437 trials
Atrial Fibrillation
Primary: Number of Subjects That Achieved Freedom From AF/AFL/AT (Atrial Fibrillation/Atrial Flutter/Atrial Tachycardia) With or Without the Use of Anti-arrhythmic Drugs After a…
Chronic Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12) — 84.8 percentage of participants
Obesity · Body Weight · Fat Burn
Primary: Change in Body Fat Percentage — -1.7556; 0.280 Percentage of Body Fat — p=<0.01
Migraine · Headache · Migraine Headache
Primary: Total Number of Responders — 17 Participants
Spastic Hemiparesis
Primary: Percentage of Responder Participants at Week 6 After the Second Injection, According to Composite Active Range of Motion (AROM) in the Primary TT Limb — 72.1 percentage…
Chronic Obstructive Pulmonary Disease · Asthma
Primary: Number of Participants With Inhaler Misuse Pre- and Post-VME — 83; 24 participants
Septic Shock
Primary: Delta SOFA Score — -1.8; -0.34; -1.68; -2.15 units on a scale
ADHD
Primary: Swanson, Kotkin, Agler, M-Flynn and Pelham (SKAMP)-Combined Scores During the Full-Day Laboratory Classroom — 11.4; 18.2 score on SKAMP-C — p=<0.0001
Cystic Fibrosis
Primary: Number of Participants With Treatment-Emergent Adverse Events — 14; 7; 7; 4 Participants
Bladder Carcinoma
Primary: Patient Total Equivalent Analgesic Requirement (Morphine Equivalents) — 297.65; 396.16 Total oral morphine equivalents in mg
Chronic Hepatitis B
Primary: Mean Change in Serum HBsAg From Baseline to Week 24 — -0.079; -0.096; -0.016; -0.135 log10 IU/mL — p=0.805
Understanding Cochrane Systematic Reviews
Primary: Understanding — 6.0; 6.0; 5.0 units on a scale
Type 2 Diabetes Mellitus, CKD and Albuminuria
Primary: Adjusted Mean Change From Baseline in Glycosylated Haemoglobin (HbA1c): Comparison of Dapagliflozin 10 mg Plus Saxagliptin 2.5 mg and Placebo at Week 24 — -0.85; -0.27…
Multiple Myeloma
Primary: Maximum Tolerated Dose (Phase 1) — 0; 1; 0; 0 Participants
Healthy
Primary: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) — 769.069; 771.680; 834.680; 810.054 µg·h/mL